Active substance
Results for the substance romosozumab
1 result
About this active substance
Romosozumab is a monoclonal antibody used in the treatment of osteoporosis in postmenopausal women at high risk of fractures. It works by inhibiting sclerostin, a protein that negatively regulates bone formation, thereby stimulating new bone formation and reducing bone resorption.
Romosozumab is administered as a subcutaneous injection, usually once a month, for up to 12 months. It is indicated for patients who cannot tolerate other osteoporosis therapies or who are at high risk of fractures.
Common side effects include joint pain, headache, and injection site reactions. In rare cases, severe adverse reactions such as cardiovascular events or osteonecrosis of the jaw may occur. Regular monitoring of bone mineral density and overall health is essential during treatment.
Romosozumab represents an innovative therapeutic option for patients with severe osteoporosis, helping to reduce fracture risk and improve bone health.
Romosozumab is administered as a subcutaneous injection, usually once a month, for up to 12 months. It is indicated for patients who cannot tolerate other osteoporosis therapies or who are at high risk of fractures.
Common side effects include joint pain, headache, and injection site reactions. In rare cases, severe adverse reactions such as cardiovascular events or osteonecrosis of the jaw may occur. Regular monitoring of bone mineral density and overall health is essential during treatment.
Romosozumab represents an innovative therapeutic option for patients with severe osteoporosis, helping to reduce fracture risk and improve bone health.